How much revenue does Hunan Warrant Pharmaceutical make?

Hunan Warrant Pharmaceutical reported 1.50 billion CNY in revenue for fiscal year 2025, up 6.5% from 1.41 billion CNY in fiscal year 2024. In Q1 2026 revenue was 324.55 million CNY.

Where does Hunan Warrant Pharmaceutical make most of its revenue?

East China: 44% of revenue by region in fiscal year 2023, followed by Central China (13%).

What companies are similar to Hunan Warrant Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ), Dezhan Healthcare Company Limited (000813.SZ), Cisen Pharmaceutical Co., Ltd. (603367.SS), Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ).

Hunan Warrant Pharmaceutical Co.,Ltd (688799.SS) Stock

About Hunan Warrant Pharmaceutical Co.,Ltd

Hunan Warrant Pharmaceutical Co.,Ltd manufactures and sells pharmaceutical products in China. It offers medicines in the areas of digestive, respiratory, anti-infective, diabetes, Hypertension, calcium supplementation cardiovascular, cerebrovascular, and other fields. The company also provides APIs and Intermediates. Hunan Warrant Pharmaceutical Co.,Ltd was founded in 2001 and is based in Changsha...

At a glance

Hunan Warrant Pharmaceutical reported revenue of 1.50 billion CNY for fiscal year 2025, up 6.5% from fiscal year 2024, and net income of 238.28 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 324.55 million CNY, down 3.5% from a year before. East China was its largest region in fiscal year 2023, with 44% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.